These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35241461)

  • 21. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
    Goldie SJ; Kuhn L; Denny L; Pollack A; Wright TC
    JAMA; 2001 Jun; 285(24):3107-15. PubMed ID: 11427139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Cost-Effectiveness of Visual Triage of Human Papillomavirus-Positive Women in Three Low- and Middle-Income Countries.
    Campos NG; Jeronimo J; Tsu V; Castle PE; Mvundura M; Kim JJ
    Cancer Epidemiol Biomarkers Prev; 2017 Oct; 26(10):1500-1510. PubMed ID: 28710075
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
    Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
    BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Field Evaluation of Xpert HPV Point-of-Care Test for Detection of Human Papillomavirus Infection by Use of Self-Collected Vaginal and Clinician-Collected Cervical Specimens.
    Toliman P; Badman SG; Gabuzzi J; Silim S; Forereme L; Kumbia A; Kombuk B; Kombati Z; Allan J; Munnull G; Ryan C; Vallely LM; Kelly-Hanku A; Wand H; Mola GDL; Guy R; Siba P; Kaldor JM; Tabrizi SN; Vallely AJ
    J Clin Microbiol; 2016 Jul; 54(7):1734-1737. PubMed ID: 27076663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.
    Goldie SJ; Levin C; Mosqueira-Lovón NR; Ortendahl J; Kim J; O'Shea M; Diaz Sanchez M; Mendoza Araujo MA
    Rev Panam Salud Publica; 2012 Dec; 32(6):426-34. PubMed ID: 23370186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
    Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
    Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis.
    Messoudi W; Elmahi T; Nejjari C; Tachfouti N; Zidouh A; Saadani G; Moriña D; Diaz M
    J Med Econ; 2019 Nov; 22(11):1153-1159. PubMed ID: 31135231
    [No Abstract]   [Full Text] [Related]  

  • 32. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries.
    Campos NG; Sharma M; Clark A; Lee K; Geng F; Regan C; Kim J; Resch S
    Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():47-56. PubMed ID: 28691334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges.
    Pimple SA; Mishra GA
    Minerva Ginecol; 2019 Oct; 71(5):365-371. PubMed ID: 31698891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimating the value of point-of-care HPV testing in three low- and middle-income countries: a modeling study.
    Campos NG; Tsu V; Jeronimo J; Mvundura M; Kim JJ
    BMC Cancer; 2017 Nov; 17(1):791. PubMed ID: 29178896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
    Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
    Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs and cost-effectiveness of cervical cancer screening strategies in women living with HIV in Burkina Faso: The HPV in Africa Research Partnership (HARP) study.
    Devine A; Vahanian A; Sawadogo B; Zan S; Bocoum FY; Kelly H; Gilham C; Nagot N; Ong JJ; Legood R; Meda N; Miners A; Mayaud P;
    PLoS One; 2021; 16(3):e0248832. PubMed ID: 33765011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of cervical-cancer screening in five developing countries.
    Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
    N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching clinic-based cervical cancer screening programs to human papillomavirus self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
    Pedersen K; Portnoy A; Sy S; Hansen BT; Tropé A; Kim JJ; Burger EA
    Int J Cancer; 2022 Feb; 150(3):491-501. PubMed ID: 34664271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L; Rémy V; Oyee J; Largeron N
    Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.